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A non-invasive diagnostic approach is crucial for the evaluation of severity of liver disease, treatment decisions, and assessing 
drug efficacy. This study evaluated plasma proteomic profiling via an N-terminal isotope tagging strategy coupled with liquid 
chromatography/Fourier transform ion cyclotron resonance mass spectrometry measurement to detect liver fibrosis staging. 
Pooled plasma from different liver fibrosis stages, which were assessed in advance by the current gold-standard of liver biopsy, 
was quantitatively analyzed. A total of 72 plasma proteins were found to be dysregulated during the fibrogenesis process, and 
this finding constituted a valuable candidate plasma biomarker bank for follow-up analysis. Validation results of fibronectin by 
Western blotting reconfirmed the mass-based data. Ingenuity Pathways Analysis showed four types of metabolic networks for 
the functional effect of liver fibrosis disease in chronic hepatitis B patients. Consequently, quantitative proteomics via the 
N-terminal acetyl isotope labeling technique provides an effective and useful tool for screening plasma candidate biomarkers 
for liver fibrosis. We quantitatively monitored the fibrogenesis process in CHB patients. We discovered many new valuable 
candidate biomarkers for the diagnosis of liver fibrosis and also partly identified the mechanism involved in liver fibrosis dis-
ease. These results provide a clearer understanding of liver fibrosis pathophysiology and will also hopefully lead to improve-
ment of clinical diagnosis and treatment. 
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Hepatitis B virus (HBV) infection affects 350 million indi-
viduals worldwide [1] and more than 100 million individu-
als in China. Liver fibrosis is a common response to CHB 
infection and might result in potentially lethal sequelae, 
which progress to cirrhosis in 12%–20% of patients, and 
compensated cirrhosis progresses to hepatic decompensa-
tion and hepatocellular carcinoma within five years in 
20%–25% and 6%–16% of patients, respectively. Approxi-
mately 250000 deaths occur each year worldwide as a con-
sequence of fulminant hepatic failure, cirrhosis and hepato-
cellular carcinoma [1,2]. Liver disease is not an incurable 
disease, because liver fibrosis and cirrhosis are reversible, 
and accurate diagnosis is crucial for evaluation of the sever-
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ity of the disease, for treatment decisions, and for assessing 
drug efficacy [3]. Clinically, it is always difficult to make a 
noninvasive diagnosis of liver fibrosis. Liver biopsy is cur-
rently the gold-standard procedure for assessing the degree 
of fibrosis, but it has several disadvantages such as costly 
procedures, poor patient compliance, discomfort for the 
patient, the risk of poorly standardized collection of liver 
tissues, and limited usefulness for dynamic surveillance and 
follow-up. Considering these limitations, accurate and reli-
able noninvasive methods to assess the severity of hepatic 
fibrosis are urgently needed [4].  
Plasma biomarkers offer an attractive alternative to liver 
biopsy because they contain considerable information on 
liver conditions and they are less invasive than biopsies, 
they may allow dynamic calibration of fibrosis, and may be 
more economic. Several markers and marker sets have 
shown promise towards this goal [5], but none of them fully 
satisfies the above requirements, especially for accurate 
staging of liver fibrosis in chronic hepatitis B (CHB) pa-
tients. Therefore, more suitable plasma markers with a high 
specificity and good sensitivity are required for non-inva-     
sive monitoring of liver fibrosis and its progression.  
Proteomics is used to determine the expression and dy-
namics of many proteins, and is especially suitable for ex-
ploration of disease biomarkers. Comparison of proteomes 
of disease and control plasma samples has been shown to be 
a suitable approach for discovering plasma biomarkers of 
liver diseases [6]. Quantitative proteomic techniques based 
on stable isotope labeling are increasingly being applied in 
biomarker studies [7,8]. The N-terminal acetyl isotope 
(d0/d6) labeling technique shows great potential in bio-
marker detection with its high-throughput identification and 
accurate quantification of proteins, as well as being a simple 
procedure. Leading edge liquid chromatography/Fourier 
transform ion cyclotron resonance mass spectrometry (LC- 
FTICR-MS) technology’s superior sensitivity and powerful 
measurement can also contribute to plasma biomarker de-
tection. Therefore, this technique was selected as the strat-
egy for our study [9]. 
Based on the histology of chronic liver diseases, this 
study was designed to explore candidate plasma biomarkers 
that are correlated with the stages of pathology with the 
quantitative proteomics technique, N-terminal acetyl label-
ing. We aimed to investigate new candidate plasma bio-
markers for the accurate and noninvasive diagnosis of liver 
fibrosis in CHB patients to improve staging of liver disease 
and to assess the effect of treatment and predict disease 
progression. 
1  Materials and methods 
1.1  Patient selection 
Liver biopsies were obtained from consecutive CHB pa-
tients in the People’s Hospital of Peking University and 302 
Military Hospital of China. The study was approved by the 
local ethics committee and written informed consent was 
obtained for all participants. Clinical, hematological, and 
biochemical data were recorded from each patient within 
one week of liver biopsy. The included patients all had se-
rum positive for hepatitis B surface antigen, hepatitis B 
e-antigen, and hepatitis B virus DNA for at least six months. 
Serum levels of alanine aminotransferase were between two 
and 10 times the upper limit of normal within six months 
before liver biopsy and there was no prior therapy with an-
tiviral or immunoregulating drugs. Those patients who had 
positive laboratory tests for human immunodeficiency virus, 
positive serum for anti-hepatitis C virus (anti-HCV), and/or 
HCV RNA, decompensated liver disease, alcoholic liver 
disease, suspected autoimmune diseases with an antinuclear 
antibody titer greater than 1:160, serum creatinine 1.5 times 
greater than normal, and inadequate hematological function, 
were all excluded.  
1.2  Histological examination 
All selected patients received a liver biopsy directed by ul-
trasonography within one week after inclusion. A quick-cut 
(8-Light Company, Japan) or Menghini needle (14 G) was 
used for this procedure. The biopsy specimens were fixed 
with 10% formalin, routinely embedded in paraffin, and the 
tissue sections were processed with hematoxylin and eosin, 
Masson’s trichrome, and reticular fiber staining (Appendix 
Figure S1 in the electronic version). A minimum length of 
at least 1 cm of the liver biopsy and at least six portal tracts 
were required for diagnosis. Five fibrosis stages were de-
termined using Scheuer’s classification [10]: stage 0 (F0), 
no fibrosis; stage 1 (F1), enlarged fibrotic portal tracts; stage 
2 (F2), periportal or portal-portal septa, but intact architecture; 
stage 3 (F3), fibrosis with architectural distortion, but no ob-
vious cirrhosis; and stage 4 (F4), cirrhosis. Liver fibrosis 
was considered significant when it spread beyond the portal 
tract (stages 2, 3, or 4), whereas it was considered insignifi-
cant when it was absent or restricted to the portal tract 
(stages 0 or 1, respectively). All the sections were blindly 
and independently assessed by two pathologists from the 
above hospitals. 
Detailed information for patient characteristics such as 
sex, age and type of disease is shown in Table 1 and Ap-
pendix Table S1 in the electronic version. 
1.3  Plasma treatment  
After obtaining informed consent, we collected 5 mL fast-
ing blood samples by venipuncture and a BD Vacutainer K3 
EDTA (BD Biosciences, Franklin Lakes, NJ, USA). Plasma 
was obtained by centrifuging the blood at 2000×g for 15 
min at 4°C, and then supernatant was transferred to fresh 
microtubes (Axygen Scientific, Inc., USA). They were cen- 
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Table 1  Characteristics of CHB patients with different liver fibrosis stagesa) 
Fibrosis stage F0 F1 F2 F3 F4 
Age (SD) 32 (10.6) 30.2 (13.5) 31.5 (8.3) 37.5 (10.2) 36.4 (11.9) 
Sex (F/M) 4/6 4/6 4/6 3/6 3/7 
Race (Han) 10 10 10 9 10 
Fibrosis activity G0 G2 G2 G2 G2 
HCV 0 0 0 0 0 
HIV 0 0 0 0 0 
Alcoholic liver disease 0 0 0 0 0 
Autoimmune diseases 0 0 0 0 0 




trifuged at 15000×g for 15 min at 4°C and stored at −70°C 
before analysis. All patients had been fasting for at least 6 h 
before blood sampling. To remove albumin and immu-
noglobulin from human plasma, the samples were treated 
with ProteoExtract™ Removal Kits (Merck Company, 
Germany) according to the manufacturer’s instructions 
(Appendix Figure S2 in the electronic version). The treated 
samples were measured at 595 nm for protein concentration 
with a Protein DC kit (Bio-Rad, USA) based on the Lowry 
method. To evaluate the reproducibility and effect of re-
moval, all the treated samples were separated with 12% 
sodium dodecylsulfate polyacrylamide gel electrophoresis 
(SDS-PAGE), 30 μg protein per lane, and stained by 
SYPRO-Ruby (Bio-Rad). The main procedure of this re-
search is shown in Figure 1. 
1.4  Plasma pooling and SDS-PAGE fractionation 
All the individual plasma included was measured for protein 
concentration with a Protein DC kit (Bio-Rad), and then all 
the individual plasma in the same group was pooled equally 
before the following fractionation, which represents the 
corresponding fibrosis stage (F0–F4). All the plasma from 
the five groups was pooled equally as the intra-standard (P). 
Each group (F0–F4, pooled and treated plasma) was com-
pared with the same intra-standard (P), and the correspond-
ing ratio value was used for their corresponding protein’s 
quantified data. A total of 50 µg treated plasma protein from 
each group (P, F0–F4) was boiled in SDS-PAGE sample 
buffer, resolved on a 12% SDS-PAGE gel and stained with 
Coomassie Blue. Each group in a gel lane with its 
neighboring intra-standard gel lane was excised in a parallel 
manner, and the gel was divided horizontally into 15 sec-
tions in total and processed separately for tryptic digestion 
as described below (Appendix Figure S3 in the electronic 
version).  
1.5   In-gel tryptic digestion 
The gel particles were washed twice with a suitable volume 
(to immerse the gel particles) of 25 mmol L−1 ammonium  
 
Figure 1  Schematic diagram of human plasma quantitative proteome 
analysis using the N-terminal acetyl labeling approach. Pools of all the 
plasma samples from F0 to F4 along with the same intra-standard (intra 
standard plasma, pool of all the plasma included in this study) were simi-
larly processed and fractionated by SDS-PAGE and combined after differ-
ential isotopic labeling. Individual fractions were analyzed by LC-MS/MS.  
Data were processed using “MSAQ”. 
bicarbonate/50% acetonitrile (Sigma, USA). The super-
natant was removed and discarded after each wash. The 
destained gel particles were dried for 30 min in a Speed-Vac 
(Thermo Electron, USA), and then rehydrated in 10 μL 25 
mmol L−1 ammonium bicarbonate buffer containing 0.1 μg 
μL−1 trypsin at 4°C for 30 min. The gels were overlaid with 
25 mmol L−1 ammonium bicarbonate buffer and incubated 
12–16 h at 37°C. The peptides were extracted by 5% 
trifluoroacetic acid (TFA) and then by 50% acetonitrile/5% 
TFA. The supernatant was removed after each step and 
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saved in tubes. The peptides were dried in the Speed-Vac 
and stored at −80°C. 
1.6  N-terminal isotope labeling 
The ε-amino group of all lysine was guanidinated as de-
scribed previously [11,12] with some modifications. An equal 
volume of 1 mol L−1 O-methylisourea (dissolved in 0.5 mol 
L−1 carbonate buffer, adjusted to pH 11 with 1 mol L−1 
NaOH) was added to the peptide mixture and incubated at 
37°C for 2 h. The solutions were adjusted back to pH 8.0 with 
1 mol L−1 HCl for acetylation. A total of 200 μL of borate 
buffer was added to the solution for maintenance of the pH 
value. D0- and d6-acetic anhydrides were diluted into 1 mol 
L−1 with tetrahydrofuran, and then they were added to the 
guanidinated peptides. The amount of diluted acetic anhy-
dride used was 1 μL per 50 μg digested peptides. The acety-
lation reaction was performed at room temperature for 1 h. 
N-hydroxylamine was used to hydrolyze the esters formed 
during the acetylation reaction by incubation for 30 min (pH 
11.0). The resultant solutions were then desalted on a C18 
column, lyophilized, and stored at −20°C before use. 
1.7  Liquid chromatography coupled with tandem mass 
spectrometry (LC-MS/MS) analysis 
The resultant plasma peptides were analyzed using a 7-Tesla 
linear quadrupole ion-trap Fourier-transform ion-cyclotron 
resonance (LTQ-FT) mass spectrometer (Thermo Electron, 
San Jose, CA, USA) coupled with an Agilent 1100 
nano-flow liquid chromatography system. Reverse phase 
C18 trap columns (300 µm internal diameter×5 mm long 
column) were connected with a six-port column-switching 
valve for on-line desalting. A PicoFrit™ tip column (Bio-
Basic C18, 5 µm particle size, 75 µm internal diameter×10 
cm long column, 15 µm internal diameter at the spray tip; 
New Objective, Woburn, MA, USA) was used for the fol-
lowing separation. Elution was performed with solvent A 
(Milli-Q water, 2% acetonitrile and 0.1%TFA, v/v/v) and 
solvent B (Milli-Q water, 80% acetonitrile and 0.1%TFA, 
v/v/v). The gradient was 15%–40% B for 80 min and 
40%–100% B for 15 min. One FT full MS scan was fol-
lowed by five data-dependent LTQ MS/MS scans on the five 
most intense ions. The dynamic exclusion time was 45 s. 
Ions were accumulated in a linear ion trap controlled by the 
automatic gain control. The automatic gain control values 
were 5×105 charges for the FT full MS scan and 1×104 
charges for the LTQ MS/MS scan. The resolution was 
10000 for a FT full MS scan at 400 m/z. The temperature of 
the ion transfer tube was set at 200°C and the spray voltage 
was set at 1.8 kV. The isolation width was 4 Da and nor-
malized collision energy was 35% for the MS/MS scan. 
Mass spectra were acquired over the mass range from 400 
to 2000 m/z. 
1.8  Protein identification and quantification 
The acquired raw file was converted to *.dta files by Bio-
Works 3.2 and all the *.dta files were merged into one 
*.mgf format file by a script named merge.pl. The *.mgf file 
was then searched against the international protein index 
(IPI) Human v3.07 (ftp://ftp.ebi.ac.uk/pub/databases/IPI/  
old/HUMAN/ipi.HUMAN.v3.07.fasta.gz) by the in-house 
MASCOT (version 1.9). The d0-acetylation (+42.0106 Da) 
and d3-acetylation (+45.0294 Da) of the peptide N-terminus, 
guanidination of the lysine residue (+42.0218 Da), and cys-
teine carbamidomethylation (+57.0214 Da) were set as 
fixed modifications. The maximal allowable miss-cleavage 
sites were two, and the mass tolerances for peptide and 
fragment ions were 1.5×10−5 and 1.0 Da, respectively. There 
was at least 95% confidence that each identified peptide had a 
score greater than 27. Each identified protein had at least one 
unique positive peptide that was not shared with any other 
protein. Based on the mascot results, the monoisotopic peak 
ratio between the heavy-labeled peptides and the 
light-labeled peptides was automatically calculated by a 
graphic user interface program called “mass spectrometry 
quantification with acetylation labeling” (MSAQ) [13] de-
veloped in house. The basic quantitative information was 
from the intensities of the pair of parent ions of the light- or 
heavy-labeled peptides in the MS full scans. The peptide 
pairs were accurately extracted by matching the m/z of the 
parent ion with the peaks in the MS full scan around the 
MS/MS scan time, and the intensity ratio of the labeled pep-
tide pairs was computed. Because the 4th isotopic peak of 
the light-labeled peptide might overlap with the monoiso-
topic peak of the heavy-labeled peptide, especially when the 
mass is greater than 1500 Da, the observed ratio could be 
larger than the true ratio. According to the theory that iso-
topic distribution can be calculated by a polynomial algo-
rithm, the overlapping portion was subtracted. After the 
steps mentioned above, the mean and standard deviation of 
the ratios of the pairs of each peptide were calculated and 
used as the final quantitative ratio of the peptide. To main-
tain data quality, the minimal signal/noise (S/N) of the pairs 
was set to greater than two, which was read from the *.raw 
file by the Xcalibur Development Kit (XDK) API function.  
1.9  Ingenuity pathway analysis (IPA) 
Predominant interaction networks of differentially expressed 
proteins were conducted using IPA on a web-delivered ap-
plication (www.ingenuity.com) [14]. The biological func-
tions assigned to each network were ranked according to the 
significance of that biological function to the network. 
Fischer’s exact test was used to calculate the P-value.  
1.10  Western blotting verification 
Samples were run on 12% SDS-PAGE gels and transferred 
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onto polyvinylidene difluoride membranes in a trans-blot 
electrophoresis transfer cell (Bio-Rad). The membranes 
were blocked overnight at 4°C in 20 mmol L−1 Tris-HCl, 
140 mmol L−1 NaCl, pH 7.5, and 0.05% Tween-20 (TBST) 
containing 5% skim milk. The primary antibody used was 
fibronectin antibody (diluted 1:1000, Santa Cruz Biotech-
nology, USA). Membranes were incubated at room tem-
perature for 1 h with each primary antibody, and then they 
were washed three times with 0.05% Tween-20 and incu-
bated with horseradish peroxidase-conjugated secondary 
antibody (diluted 1:10000, Santa Cruz Biotechnology) for  
1 h at room temperature. Visualization of the immunoreac-
tive proteins was accomplished using enhanced chemilumi-
nescence reagents (Santa Cruz Biotechnology). All the 
membranes were exposed on the same X-ray film and 
scanned by a GS-710 scanner (Bio-Rad). 
2  Results and discussion 
2.1  Results 
We quantified a total of 1109 plasma proteins, among which 
72 proteins (ratio (max/min)≥1.5, quantified peptides≥2, 
expression in all liver fibrosis stages) were dysregulated in 
the liver fibrosis stages (F0–F4), and this provided a valu-
able reference and biomarker bank for liver fibrosis detec-
tion. The data are listed in Appendix Tables S2 and S3 in 
the electronic version. Some mass spectra for selected pep-
tides are shown in Figure 2. Other mass spectra for selected 
peptides are attached in Appendix Figure S4 in the elec-
tronic version.  
Detailed information with all quantitative data is listed in 
Appendix Table S3.  
2.2  Western blot verification 
To validate reliability of the NIT (N-terminal isotope tag-
ging) results, one of the identified proteins, fibronectin, was 
selected for further examination by Western blotting. This 
protein has been reported in HCV patients, but there are no 
reports in CHB patients, especially for liver fibrosis stages. 
We showed a similar expression to the data from the NIT 
proteomic technique, which re-confirmed the proteomic 
data as well as their potential clinical use (Figure 3). 
2.3  Discussion 
The search for disease-specific biomarkers from human 
plasma is gaining increasing attention because of significant 
advances in proteomic technology and their potential for 
discovering novel disease biomarkers [15]. Noninvasive 
plasma biomarker diagnosis for hepatic fibrosis has become 
popular because it provides considerable information, which 
is crucial for evaluation of the severity of the disease, for 
treatment decisions, and for assessing drug efficacy. Cur-
rently, the available noninvasive methods of assessing liver 
fibrosis in CHB patients are imperfect and lack accuracy  
 
 
Figure 2  Mass spectra for a selected peptide of transthyretin with the ratios of the five different liver fibrosis stages. The peptide shows up-regulated ex-
pression with development of liver fibrosis, especially during the F3 and F4 stages. 
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Figure 3  MS-based quantitative pattern and Western blotting result for 
fibronectin in the five different liver fibrosis stages (F0–F4). The fi-
bronectin ratio value was obtained by MS-based quantitation of seven 
peptides, with the corresponding standard error indicated on the histogram.  
The results show satisfactory agreement with the Western blotting results. 
and reliability [16,17]. Therefore, more reliable biomarkers 
are required to solve this issue.  
2.3.1  NIT technology is reliable and effective for bio-
markers’ screening 
Based on the high mass accuracy and sensitivity instrumen-
tation of LTQ-FT, stable isotope labeling techniques produce 
reliable results in quantitative proteome analysis [18,19]. 
With its advantages of simple labeling procedures, low cost, 
full labeling ability for all the proteins, and a high accuracy 
and sensitivity, N-terminal isotope labeling technology is a 
reliable and powerful strategy for biomarker analysis 
[20,21]. We quantified a total of 1109 proteins. Based on 
the aim of stringently screening with a high confidence, we 
only chose proteins that were markedly dysregulated in all 
the five groups (F0–F4) and had at least two peptides quan-
tified in the same protein. As a result, 72 different proteins 
were found in the quantitative analysis among all the liver 
fibrosis stages, and we were then able to construct a reliable 
dataset for detection of liver fibrosis. 
2.3.2  A candidate biomarker dataset with new properties  
Liver fibrosis is a dynamic and multi-factorial process in-
volving complex interactions within many types of cell types. 
When this process is disrupted there is an accumulation of 
several distinct extracellular matrix (ECM) proteins [22]. 
Hepatitis B causes liver fibrosis through direct cytopathic 
means, direct and indirect interactions with hepatic stellate 
cells (HSCs), as well as activation of the immune system. 
Plasma proteins contain many messages for the fibrogenesis 
process both directly and indirectly. In this study, the sig-
nificantly dysregulated proteins were related to several 
types of mechanisms, such as HSC dysfunction, immune 
factor impairment, lipid metabolism, protein synthesis in the 
liver, and hematological system development. Some of 
these candidate proteins are discussed below. 
(i) Proteins related to HSC dysfunction.  HSCs play a 
central role in the fibrogenesis process, and HSC dysfunc-
tion is reflected in several aspects. Gelsolin, which was one 
of the candidate proteins for LF diagnosis in our study, is an 
actin-fragmenting cytoplasmic protein and it plays an im-
portant role in HSC growth regulation, and it is suggested to 
be involved in cell motility, to inhibit apoptosis and to have 
a protective role in liver tissue [23,24]. Gelsolin levels are 
decreased during liver injury or liver cancer [25]. We found 
that this protein had down-regulated expression from the F3 
to F4 stages, which suggests that liver cell apoptosis was 
intensified and it indicates its potential value for clinical 
diagnosis. 
Fibronectin is a glycoprotein, the major sources of which 
are hepatocytes, Kupffer cells and endothelial cells. It has 
many biological functions including adhesion between cells, 
immunity, blood coagulation and platelet aggregation. It has 
been reported to be down-regulated in liver cirrhosis in 
HCV patients [26,27]. However, its sensibility and accuracy 
for liver fibrosis staging, especially for CHB patients, is 
unknown. We found that fibronectin was down-regulated 
between the F3 and F4 stages, which shows its potential 
power for liver fibrosis staging. 
(ii) Proteins related to liver synthesis and function.  Pro-
tein synthesis is mostly carried out in the liver. Any damage 
to the liver, including liver fibrosis disease caused by HBV, 
will be reflected by plasma proteins.  
Hemopexin is a plasma glycoprotein that is expressed 
only in the liver. It is synthesized at a lower rate in the fetal 
liver than in the adult [28–30]. Hemopexin is essential for 
protection from splenomegaly and liver fibrosis resulting 
from intravascular hemolysis. In our study, we observed 
down-regulated expression of hemopexin, which suggests 
that it has a dysfunctional role in liver fibrosis disease. 
Vitronectin is a multifunctional plasma glycoprotein 
produced by hepatocytes. It has been extensively studied as 
a cell adhesion molecule and may play an important role in 
the progression of liver disease and/or in hepatic fibrosis 
through its collagen-binding domain [31,32]. We found that 
vitronectin was up-regulated in this study, which suggests 
that it could be a potential biomarker for fibrogenesis. 
Orosomucoid (alpha1-acid glycoprotein) is a polymor-
phic acute-phase reactant with immunosuppressive proper-
ties and has been found to be significantly increased in pa-
tients with different types of carcinomas [33]. Previous in-
vestigations have suggested that orosomucoid and other 
acute-phase reactants may act as blocking factors protecting 
tumor cells against immunological attack, thereby contrib-
uting to the “immune escape” of the tumor. It is required to 
maintain the high capillary permselectivity required for 
normal homeostasis [34]. In our study, we observed that 
orosomucoid tended to be up-regulated with liver fibrosis 
development. This result should be helpful for detection of 
liver fibrosis as well for determining its molecular mecha-
nism. 
Amyloid P component is a plasma protein with a possible 
role in liver protein synthesis and it might be useful as a 
marker of liver involvement [35,36]. Amyloid P component 
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plasma levels and the degree of disease activity and hepatic 
impairment are closely correlated in patients with liver dis-
eases. In the current study, amyloid P component expression 
was decreased in F4/F2. This result may be helpful for rou-
tine judgments.  
Ficolin is synthesized in the liver, and it plays an important 
role in the lectin pathway of the complement system [37,38]. 
Its down-regulated expression following the fibrogenesis 
process potentially makes it a suitable biomarker in this 
study. We found that both isoforms of kininogen of this pro-
tein [39] were down-regulated in the F4 stage. 
(iii) Proteins related to immune factors.  Chronic viral 
diseases of the liver are associated with changes in im-
mune reactions mediated by immune effector mechanisms 
[40]. Immunoglobulin is one of the main proteins in 
immune responses and is expressed differently in different 
diseases. Recently, it was reported that it appeared to be 
correlated with the degree of fibrosis with different gly-
cosylation [41]. In our study, we also observed several 
types of immunoglobulin proteins or peptides related to 
different liver fibrosis stages. Different expression of this 
protein may be related to the natural history of the disease 
and it may be useful in the noninvasive detection of fibro-
sis and cirrhosis. We found that the immune-related pro-
teins, IGKV1-5/3-25/2 protein and complement factor 
C4-A, 4B and 5 all showed dysregulated expression during 
liver fibrosis development, which suggests that they play 
an important role participating an alternative pathway in 
HBV disease. 
(iv) Proteins related to lipid metabolism.  Several 
types of apolipoprotein are clinically used as noninvasive 
biomarkers for liver fibrosis diagnosis in HCV patients, 
non-alcoholic fatty liver disease and carcinoma [42–44]. 
One type of pathway that affects disease development is 
apolipoprotein entering cells via the low-density lipopro-
tein receptor. We identified apolipoprotein groups includ-
ing apolipoprotein A-IV, B, D, E, L, and M, which all 
showed dysregulated expression during the fibrogenesis 
process, which indicates that lipid metabolism plays an 
important role during fibrogenesis development in CHB 
patients.  
(v) Proteins related to development of the hematological 
system.  Hemoglobin from erythrocytes is a source of iron 
that accumulates in the liver, and this mediates liver cell 
damage in viral hepatitis [45]. Using the SELDI (surface 
enhanced laser desorption ionization) system, hemoglobin 
was found to be correlated with liver fibrosis in CHB pa-
tients [46]. We found three types of subunits of hemoglobin, 
which could be used to differentiate between different 
stages of fibrosis in CHB patients.  
The renin-angiotensin system regulates fibrosis [47]. As 
a principal effector molecule of the renin-angiotensin, an-
giotensinogen is mainly produced in the liver, and it played 
multi-roles in human HSCs and liver cirrhosis in patients 
with chronic hepatitis B [48]. In our study, we found that 
this protein’s expression was up-regulated in the F2 stage 
compared with that in other liver fibrosis stages in CHB 
patients.  
(vi) Proteins grouped as enzymes.  Several types of en-
zymes have been used as biomarkers for the diagnosis of 
liver disease [49–51]. Aldehyde dehydrogenase has previ-
ously been reported to play a pathogenetic role in the de-
velopment of alcoholic liver disease [52,53]. In the current 
study, it was down-regulated in the F3 and F4 stages, sug-
gesting a functional effect by hepatitis B disease as well as 
its potential for diagnosis. 
Paraoxonase-1 is an esterase that degrades oxidized lip-
ids, and it is associated with hepatic disease [54]. We found 
that paraoxonase-1 expression was up-regulated, which 
makes this protein a suitable candidate marker monitoring 
LF process.  
(vii) Other candidate proteins.  Among the candidate 
proteins, several of them were dysregulated in the fibro-
genesis process. Alpha-2-glycoprotein-1 is a plasma protein 
of unknown function, which has been reported as a bio-
marker for some diseases including microbial infections and 
cancer [55,56]. In this study, it was up-regulated in F3 stage, 
which would be a valuable candidate protein for LF diagno-
sis. Serpin peptidase inhibitor has been reported as a bio-
marker for several diseases [57,58]. A recent report also 
showed its biomarker potential in fibrosis progression in 
HCV patients [59]. Different types of serpin peptidase in-
hibitors (clade A, member 8, clade C&D, and F&G) in our 
study all showed increased expression in the F4 stage, 
which suggests their potential for liver fibrosis detection. 
Clusterin has been reported to be a biomarker for several 
diseases [60–62], and its overexpression occurs in various 
human malignancies [63]. In the current study, clusterin 
showed dysregulated expression, which should be useful 
information for liver fibrosis analysis. Transthyretin is pri-
marily synthesized by the choroid plexus and can bind to 
beta-amyloid peptide. Several diseases have been associated 
with this protein [64,65]. It may also be a potential bio-
marker for the F1 and F4 stages in CHB patients. 
It is necessary to mention that there are some proteins 
only with its molecular weight or CDNA code or hypo-
thetical protein, but they also showed close correlation with 
LF stages in CHB patients. Further studies are required to 
validate their potential value in detail. It should also be 
noted that some of our identified proteins are different iso-
forms, truncated forms or post-translational modifications 
such as phosphorylation. Therefore, the coming test of veri-
fication for these proteins should also be carried out. Our 
study provides insight into possible compensatory mecha-
nisms regarding the process of liver fibrosis as well as being 
a valuable reference for clinical diagnosis. 
2.3.3  The IPA results suggest potential mechanisms of 
fibrogenesis  
IPA is web-based software used for identifying the biological 
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mechanisms, pathways and functions most relevant to ex-
perimental datasets of interest (http://www.ingenuity.com). It 
allows profiling data to be analyzed in a systematic way 
using known pathways represented by the proteins under-
going change [66]. The identified proteins are mapped onto 
networks available in the Ingenuity Database. Using an up-
loaded file with 72 IPI proteins, four pathways were con-
structed by IPA (Appendix Figure S5 and Table S4 in the 
electronic version), which were related to cellular assembly 
and organization and development, development and func-
tion of the hepatic system, neurological disease, develop-
ment and function of the hematological system, cardiac 
damage, cardiovascular disease, and skeletal and muscular 
disorders.  
The pathogenesis of fibrosis and cirrhosis during chronic 
viral hepatitis is multi-factorial, involving recurrent liver 
injury, sustained inflammation, and differential activation of 
ECM-producing cells [67,68]. The liver is the main site for 
the synthesis and release of most of the plasma proteins, and 
when it is infected by HBV, plasma proteins are likely to be 
quantitatively and qualitatively affected. IPA analysis with 
these differentially expressed proteins could contribute to 
comprehension of the mechanism of fibrogenesis in CHB 
patients. Therefore, further studies are required on the pro-
teins related to these pathways.  
2.3.4  Possible patterns for diagnosis of liver fibrosis 
There is a growing consensus that panels of markers should 
be able to supply the specificity and sensitivity that an indi-
vidual marker lacks. An integrated test or fingerprinting 
with many differential proteins identified in this study may 
better reflect a patient’s status than one marker alone. For 
example, haptoglobin, hemoglobin, and IGLC (immu-
noglobulin-free light chains) may be coupled together when 
LF diagnosis, which should be more reliable for liver fibrosis 
diagnosis. Many other proteins could also be detected in par-
allel in follow-up analysis. However, many candidate pro-
teins found in this study have no commercially available kits 
for their detection. Therefore, protein-chip technology [69,70] 
or multiple reaction monitoring mass spectrometry technol-
ogy [71] could possibly be performed simultaneously in a 
single experiment, to detect and quantify specific proteins 
or peptides in plasma of patients with liver fibrosis to de-
termine the degree of hepatic fibrosis. A number of studies 
have shown the feasibility of such an approach [72]. 
3  Conclusion 
Further study is required to validate the use of this model in 
CHB patients in a prospective manner with a greater num-
ber of valid plasma samples. Candidate biomarkers should 
also be tested in CHB patients on a large scale with suitable 
verification methods, such as enzyme-labeled immunosor-
bent assay or multiple reaction monitoring, to determine 
their general applicability to fibrosis staging and, ultimately, 
for the potential of plasma proteomics as noninvasive 
markers of fibrosis and cirrhosis.  
Overall, in our study, N-terminal isotope tagging strategy, 
which is a reliable, cost-effective and undemanding proce-
dure in high-throughput proteomics experiments [21,73], 
showed existing and new candidate markers for fibrosis 
progression in CHB patients. These data constitute a valu-
able reference and provide new opportunities for better fol-
low-up of HBV-infected patients, which link them mecha-
nistically to the molecular events underlying liver fibrosis 
disease and detection. Ultimately, such biomarkers could 
aid clinicians in diagnosing development of liver fibrosis, 
eliminating the need for liver biopsy and allowing early 
treatment, and monitoring fibrosis development during 
therapy. 
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